Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary.

IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES
Thomas Roth, Michael J Thorpy, Clete A Kushida, Matthew Horsnell, Jennifer Gudeman
{"title":"Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary.","authors":"Thomas Roth, Michael J Thorpy, Clete A Kushida, Matthew Horsnell, Jennifer Gudeman","doi":"10.57264/cer-2023-0133","DOIUrl":null,"url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a plain language summary of a published article in the journal <i>CNS Drugs</i>. Narcolepsy is a rare sleep condition. Most people with narcolepsy experience disrupted nighttime sleep and have poor quality of sleep. Sometimes these symptoms are not easily diagnosed as a symptom of narcolepsy. Sodium oxybate is an approved treatment for narcolepsy. The only version of sodium oxybate that was available until 2023 required people to take their sodium oxybate at bedtime and then again in the middle of the night. The US Food and Drug Administration (FDA for short) has approved a once-nightly bedtime dose of sodium oxybate (ON-SXB for short, also known as FT218 or LUMRYZ<sup>™</sup>) to treat symptoms of narcolepsy in adults. These symptoms are daytime sleepiness and cataplexy, which is an episode of sudden muscle weakness. The once-nightly bedtime dose of ON-SXB removes the need for a middle-of-the-night dose of sodium oxybate. The REST-ON clinical study compared ON-SXB to a placebo (a substance that contains no medicine) to determine if it was better at treating symptoms of disrupted nighttime sleep associated with narcolepsy. This summary looks at whether; ON-SXB was better than placebo at treating symptoms of disrupted nighttime sleep.</p><p><strong>What were the results?: </strong>Compared to people who took placebo, people who took ON-SXB had fewer number of changes from deeper to lighter sleep stages and woke up less during the night. They also reported that they slept better at night and felt more refreshed when waking up in the morning. People with narcolepsy sometimes take alerting agents to help with sleepiness during the day, but alerting agents can cause difficulty sleeping at night. This study showed that people who took ON-SXB had better nighttime sleep even if they were taking alerting agents during the day. The most common side effects of ON-SXB included dizziness, nausea (feeling sick to your stomach), vomiting, headache, and bedwetting.</p><p><strong>What do the results mean?: </strong>A once-nightly bedtime dose of ON-SXB is a narcolepsy treatment option for people without the need for a middle-of-the-night dose of sodium oxybate.</p>","PeriodicalId":15539,"journal":{"name":"Journal of comparative effectiveness research","volume":" ","pages":"e230133"},"PeriodicalIF":1.9000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10734321/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of comparative effectiveness research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.57264/cer-2023-0133","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

What is this summary about?: This is a plain language summary of a published article in the journal CNS Drugs. Narcolepsy is a rare sleep condition. Most people with narcolepsy experience disrupted nighttime sleep and have poor quality of sleep. Sometimes these symptoms are not easily diagnosed as a symptom of narcolepsy. Sodium oxybate is an approved treatment for narcolepsy. The only version of sodium oxybate that was available until 2023 required people to take their sodium oxybate at bedtime and then again in the middle of the night. The US Food and Drug Administration (FDA for short) has approved a once-nightly bedtime dose of sodium oxybate (ON-SXB for short, also known as FT218 or LUMRYZ) to treat symptoms of narcolepsy in adults. These symptoms are daytime sleepiness and cataplexy, which is an episode of sudden muscle weakness. The once-nightly bedtime dose of ON-SXB removes the need for a middle-of-the-night dose of sodium oxybate. The REST-ON clinical study compared ON-SXB to a placebo (a substance that contains no medicine) to determine if it was better at treating symptoms of disrupted nighttime sleep associated with narcolepsy. This summary looks at whether; ON-SXB was better than placebo at treating symptoms of disrupted nighttime sleep.

What were the results?: Compared to people who took placebo, people who took ON-SXB had fewer number of changes from deeper to lighter sleep stages and woke up less during the night. They also reported that they slept better at night and felt more refreshed when waking up in the morning. People with narcolepsy sometimes take alerting agents to help with sleepiness during the day, but alerting agents can cause difficulty sleeping at night. This study showed that people who took ON-SXB had better nighttime sleep even if they were taking alerting agents during the day. The most common side effects of ON-SXB included dizziness, nausea (feeling sick to your stomach), vomiting, headache, and bedwetting.

What do the results mean?: A once-nightly bedtime dose of ON-SXB is a narcolepsy treatment option for people without the need for a middle-of-the-night dose of sodium oxybate.

每晚一次的氧化钠(FT218)改善了嗜睡症患者夜间睡眠中断的症状:一个简单的语言总结。
这个总结是关于什么的?这是发表在《中枢神经系统药物》杂志上的一篇文章的简明扼要的总结。嗜睡症是一种罕见的睡眠状况。大多数嗜睡症患者夜间睡眠中断,睡眠质量差。有时这些症状不容易被诊断为发作性睡病的症状。氧化钠是一种被批准的治疗嗜睡症的药物。直到2023年,唯一可用的氧酸钠版本要求人们在睡前服用氧酸钠,然后在半夜再次服用。美国食品和药物管理局(FDA)批准了一种每晚一次的睡前剂量的氧酸钠(ON-SXB),也称为FT218或LUMRYZ™,用于治疗成人嗜睡症症状。这些症状是白天嗜睡和猝倒,这是突然肌肉无力的发作。每晚一次的ON-SXB睡前剂量消除了对午夜剂量的氧化钠的需要。REST-ON临床研究将ON-SXB与安慰剂(一种不含药物的物质)进行比较,以确定它是否能更好地治疗与发作性睡病相关的夜间睡眠中断症状。这个摘要着眼于是否;ON-SXB在治疗夜间睡眠中断症状方面优于安慰剂。结果如何?与服用安慰剂的人相比,服用ON-SXB的人从深度睡眠阶段到浅睡眠阶段的变化次数更少,夜间醒来的次数也更少。他们还报告说,他们晚上睡得更好,早上醒来时感觉更精神。患有嗜睡症的人有时会在白天服用警惕性药物来帮助睡眠,但警惕性药物会导致晚上难以入睡。这项研究表明,服用ON-SXB的人夜间睡眠更好,即使他们在白天服用了警惕性药物。ON-SXB最常见的副作用包括头晕、恶心(胃部不适)、呕吐、头痛和尿床。这些结果意味着什么?每晚睡前服用一次ON-SXB是一种治疗嗜睡症的选择,不需要在半夜服用一剂氧酸钠。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of comparative effectiveness research
Journal of comparative effectiveness research HEALTH CARE SCIENCES & SERVICES-
CiteScore
3.50
自引率
9.50%
发文量
121
期刊介绍: Journal of Comparative Effectiveness Research provides a rapid-publication platform for debate, and for the presentation of new findings and research methodologies. Through rigorous evaluation and comprehensive coverage, the Journal of Comparative Effectiveness Research provides stakeholders (including patients, clinicians, healthcare purchasers, and health policy makers) with the key data and opinions to make informed and specific decisions on clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信